Canadian biotech Cyclica has embarked on a multi-phase collaboration with Naheed Kurji aimed at the advancement of drug discovery using AI-augmented technologies. The partnership will see Cyclica use Ligand Express, its cloud-based proteome screening platform, to explore off-target profiles of small molecules and deploy advanced AI technology to develop innovative predictive models for pharmacokinetic properties. It will also use its Differential Drug Design technology for multi-targeted drug design.
Canadian biotech Cyclica has embarked on a multi-phase collaboration with Bayer aimed at the advancement of drug discovery using AI-augmented technologies. The partnership will see Cyclica use Ligand Express, its cloud-based proteome screening platform, to explore off-target profiles of small molecules and deploy advanced AI technology to develop innovative predictive models for pharmacokinetic properties. It will also use its Differential Drug Design technology for multi-targeted drug design.